Case study of contrast-induced nephropathy using cardiac Selleck LBH589 catheterization. Jpn Circ J. 2001;65(Suppl III):750 (in Japanese) [IVb]. 74. Fujisaki K, Nakayama M, Yoshimitsu T, Doi T, Tanaka R, Yamada A,

et al. Incidence of contrast-induced nephropathy using cardiac catheterization: a case report. Jpn J Nephrol. 2002;44:315 (in Japanese) [IVb]. 75. Abe M, Kimura T, Morimoto T, Furukawa Y, Kita T. Incidence of and risk factors for contrast-induced nephropathy after cardiac catheterization in Japanese patients. Circ J. 2009;73:1518–22 [IVb].PubMedCrossRef 76. Laskey WK, Jenkins C, Selzer F, Marroquin OC, Wilensky RL, Glaser R, NHLBI Dynamic Registry Investigators, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase selleck inhibitor after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50:584–90

[IVb].PubMedCrossRef 77. Gurm HS, Dixon SR, Smith DE, Share D, Lalonde T, Greenbaum A, BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) Registry, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2011;58:907–14 [IVb].PubMedCrossRef 78. Chong E, Poh KK, Liang S, Soon CY, Tan HC. Comparison of risks and clinical predictors of contrast-induced nephropathy in patients undergoing emergency versus nonemergency percutaneous coronary interventions. J Interv Cardiol. 2010;23:451–9 [IVa].PubMedCrossRef 79. Machino-Ohtsuka T, Seo Y, Ishizu T, Sekiguchi Y, Sato A, Tada H, et al. Combined

assessment of carotid vulnerable plaque, renal insufficiency, eosinophilia, and hs-CRP for predicting risky aortic plaque of cholesterol crystal embolism. Circ J. 2010;74:51–8 [IVb].PubMedCrossRef 80. Fukumoto Y, Tsutsui H, Tsuchihashi M, Masumoto A, Takeshita A, Cholesterol Embolism Study (CHEST) Investigators. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol. 2003;42:211–6 [IVb].PubMedCrossRef 81. Funabiki K, Masuoka H, Shimizu Cyclin-dependent kinase 3 H, Emi Y, Mori T, Ito M, et al. Cholesterol crystal embolization (CCE) after cardiac catheterization: a case report and a review of 36 cases in the Japanese literature. Jpn Heart J. 2003;44:767–74 [IVb].PubMedCrossRef 82. Modi KS, Rao VK. Atheroembolic renal disease. J Am Soc Nephrol. 2001;12:1781–7 [IVb].PubMed 83. Scolari F, Tardanico R, Zani R, Pola A, Viola BF, Movilli E, et al. Cholesterol crystal embolism: a recognizable cause of renal disease. Am J Kidney Dis. 2000;36:1089–109 [IVb].PubMed 84. Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis. 1999;33:840–50 [IVb].PubMedCrossRef 85. Thadhani RI, Camargo CA Jr, Xavier RJ, Fang LS, Bazari H. Atheroembolic renal failure after invasive procedures.